Dr. John Cush RheumNow
1 year 6 months ago
Korean population-based study shows that from 2010 to 2023 prevalence of ank Spondylitis (AS) increased 27 per 100,000 (2010) to 82 per 100,000 (2023). Also increasing were # of pts >50 yrs (20-33%), #females (18-24%), Comorbidities, TNFi use (30-43%), while csDMARDs declined.… https://t.co/9NjU1IugaF https://t.co/kTCtIj2BjD
Dr. John Cush RheumNow
1 year 6 months ago
A substantial # of pts with inflammatory arthritis (IA) are not receiving adequate treatment for depression and anxiety(same as those IA-free controls). Canadian study of 6,951 w/ IA & depression, on 50% recv treatment & 20% psych. Rx for depression. Similar for 3,701 w/ IA &… https://t.co/CfpwEtLH3c
Dr. John Cush RheumNow
1 year 6 months ago
Systematic review of 14 studies using administrative/med. records data on >130 million people & 1 million dementia cases, finds the risk of Alzheimers/Dementia reduced w/ Antimicrobials, vaccines & NSAID antiinflammatories (but incr w/ DM drugs, vitamins, antipsychotics)… https://t.co/p79s5Pw4k2 https://t.co/9DO1WO2NuG
Schlessinger and colleagues report that US Rheumatologists generally adhere to and agree with the 2020 American College of Rheumatology (ACR) Guideline for the Management of Gout, although knowledge gaps and practice variance exists.
Novel research from the Medical University of Vienna demonstrates the plausible utility of functional precision medicine using immunophenotyping of blood cells with rheumatoid arthritis, to help guide treatment selection.
Dr. John Cush RheumNow
1 year 6 months ago
Metanalysis of 11 studies shows that curcumin (tumeric) can reduce pain, muscle damage and inflammation in athletes following vigorous physical exercise. "pre- and post-exercise curcumin consumption.. assoc w/ better outcomes in muscle recovery, pain & antioxidant capacity"… https://t.co/J07UId683Y
Dr. John Cush RheumNow
1 year 6 months ago
Congratulations to Jennifer Anolik, MD, PhD, being named chief of the Allergy, Immunology & Rheumatology at the Univ. of Rochester Medical Center; where she is also Assoc Chair of research & professor of Medicine, Pathology, Microbiology and Immunology, and director of the… https://t.co/jvRiZZ6u1q https://t.co/N2nFp8w6Yx
Dr. John Cush RheumNow
1 year 6 months ago
Head-to-Head Clinical Trials
https://t.co/kLwVKRcnna https://t.co/XDhk9VAIin
Dr. John Cush RheumNow
1 year 6 months ago
Lung Involvement in Still's Disease
A multicentre registry observational study assessed lung involvement in a cohort of Still’s disease patients, affirming pleuritis as most common and that parenchymal lung inflammatory disease is very uncommon in both children and adults.… https://t.co/bUvg4xQrsr https://t.co/fz7wiNU0Xx
Dr. John Cush RheumNow
1 year 6 months ago
“Injustice anywhere is a threat to justice everywhere.” - Martin Luther King https://t.co/y3UDZP8uTN
Dr. John Cush RheumNow
1 year 6 months ago
ACR: Congress Fails to Reform PBMs, Mitigate Medicare Cuts Save
The ACR praised the limited extension of Medicare telehealth coverage but criticized Congress for not passing measures to increase transparency in PBM practices, address insurer issues, or prevent upcoming Medicare… https://t.co/pJ5f6LvELe https://t.co/jT3UJAx5It
Dr. John Cush RheumNow
1 year 6 months ago
Population survey study of 933 gout pts (mean 58 yrs, 76% male,80% white) found total gout flare burden = 6.6 gout flares per year. Nearly 72% of gout flares were not reported, pretreated or prevented. Those less likely to report flares were young, less school, lower CCI, less… https://t.co/Z7KWk1YEFH https://t.co/0jDGNMOKjj
A retrospective study of cutaneous lupus erythematosus (CLE) patients finds an increased risk of atherosclerotic cardiovascular disease (ASCVD) on par with systemic lupus patients.
Dr. John Cush RheumNow
1 year 6 months ago
🎉 RheumNow Live 2025 is just about 2 weeks away! 🌟 Don't miss expert talks, interactive panels, networking, and the Karaoke Gong Show! Early registration extended—secure your spot now! 🗓️ Virtual & in-person options available.
https://t.co/EPZJMOGgNk https://t.co/cMoOTlWKYu

